Longer-Term Follow-Up of Western Patients Showed Improving, Favorable Trend in Overall Survival in Global Phase III HARMONi Clinical Trial for Ivonescimab Plus Chemotherapy in 2L+ EGFRm NSCLC

Summit Therapeutics (SMMT) announced statistically significant overall survival (OS) data from the Phase III HARMONi trial for its investigational bispecific antibody, ivonescimab, combined with chemotherapy, in 2L+ EGFRm NSCLC patients who progressed after 3rd generation EGFR TKI treatment. Longer-term follow-up of Western patients yielded an improved OS hazard ratio of 0.78 (nominal p=0.0332), a crucial outcome as PD-1 monoclonal antibodies have previously failed to show OS benefit in this challenging patient population. North American patients demonstrated an even stronger OS trend (HR=0.70), with the therapy maintaining an acceptable safety profile, positioning ivonescimab as a potential first-in-class treatment addressing a significant unmet medical need.

Analysis

Summit Therapeutics' Phase III HARMONi trial for ivonescimab has yielded a significant positive development, with longer-term follow-up of Western patients demonstrating a nominally statistically significant trend in Overall Survival (OS). The analysis produced an improved OS hazard ratio of 0.78 with a nominal p-value of 0.0332, crossing a key statistical threshold after the primary analysis had narrowly missed it (p=0.057). This result is highly notable as it was achieved in a 2L+ EGFR-mutated NSCLC patient population where prior Phase III trials of PD-1 monoclonal antibodies failed to show an OS benefit. The data is further bolstered by a particularly strong signal from the North American patient subset, which showed an OS hazard ratio of 0.70, with median OS not yet reached in the treatment arm versus 14.0 months for placebo. These survival data are strongly supported by the trial's other primary endpoint, Progression-Free Survival (PFS), which was highly statistically significant from the primary analysis (HR=0.52; p<0.00001). Furthermore, the drug's safety profile appears manageable and consistent, with treatment-related discontinuations (7.3% vs. 5.0%) and deaths (1.8% vs. 2.3%) comparable to the placebo-plus-chemotherapy arm, de-risking its clinical profile ahead of potential regulatory submissions.

Key Decisions for Investors

• The nominally statistically significant Overall Survival data, particularly the strong trend in North American patients (HR=0.70), materially de-risks the ivonescimab clinical program and strengthens the asset's commercial case in a difficult-to-treat cancer population.
• Given the trial's success in a setting where other immunotherapies have failed, coupled with a manageable safety profile and FDA Fast Track designation, investors should consider the heightened probability of a favorable regulatory pathway and a significant market opportunity.
• Upcoming catalysts, including final OS data from the HARMONi trial and pivotal readouts from the HARMONi-2 and HARMONi-6 studies, should be monitored closely as they will be critical for validating the drug's broader platform potential and influencing future valuation.